Pfizer Posts Lower Profit, Names Permanent CFO
Finance leaders tracking large drugmakers should weigh reported earnings of $0.56 per share against adjusted earnings of $0.87.
Updated on Nov. 3, 2026 in Corporate Finance
Live Poll
Do you trust large pharmaceutical companies to keep medicine prices fair for patients?
Pfizer reported third-quarter 2026 earnings of $3.242 billion, or $0.56 per share, down from $3.541 billion, or $0.62 per share, a year earlier. The company also named Cecile Guegan chief financial officer effective November 1, after she served as interim CFO since August 16.
Why it matters
A leadership change in the finance chair at a major drugmaker signals continuity in how the company manages its books and reporting, while the earnings decline shows the pressure on reported profit even as adjusted results remained well above GAAP figures. For operators, the gap between reported and adjusted earnings is a reminder to read the reconciliation, not just the headline number.
Pfizer's third-quarter reported earnings fell to $3.242 billion from $3.541 billion a year earlier, while revenue slipped 0.4% to $16.583 billion from $16.654 billion. Adjusted earnings were $4.985 billion, or $0.87 per share, a figure the source does not reconcile against the reported total.
The players
Pfizer
A large U.S. biopharmaceutical company that develops and sells prescription medicines and vaccines across global markets.
Cecile Guegan
Pfizer's interim chief financial officer since August, previously overseeing the company's biopharmaceutical financial operations and reporting.
The details
Reported earnings and adjusted earnings are calculated differently, and the gap between them here is substantial, with adjusted earnings of $0.87 per share against reported earnings of $0.56. Guegan had been overseeing the company's financial operations, execution, and strategic planning as interim CFO, and her permanent appointment, approved unanimously by Pfizer's board, moves that oversight into a permanent role. Her prior responsibility covered financial operations and reporting for the biopharmaceutical business across therapeutic areas and geographies.
Timeline
August 16: Guegan began serving as interim chief financial officer.
Tuesday: Pfizer announced the CFO appointment and reported third-quarter earnings.
November 1: Guegan's appointment as chief financial officer takes effect.
Market Landscape
Large drugmakers routinely report adjusted earnings that exclude items such as restructuring and acquisition costs, and the SEC requires a reconciliation to the GAAP figure under Regulation G. Pfizer's third-quarter results follow that pattern, with adjusted earnings sitting well above reported earnings.
Operators tracking public company benchmarks should compare reported and adjusted earnings side by side rather than relying on either alone. Finance teams at businesses that report adjusted figures to lenders or investors should confirm that their reconciliation to GAAP is documented and consistent quarter to quarter.
The takeaway
Read the reconciliation between reported and adjusted earnings before drawing conclusions from any single per-share figure. Track whether the new CFO's first full quarter in the role changes how the company presents its results.
Further reading
For more on how public companies report and manage their finances, browse our Corporate Finance coverage.
Source note: This article includes information reported by dpa International.
Live Poll
Do you trust large pharmaceutical companies to keep medicine prices fair for patients?
